To include your compound in the COVID-19 Resource Center, submit it here.

Actos pioglitazone regulatory update

FDA is updating the label of diabetes drug Actos pioglitazone from Takeda to warn that use of the drug for >1 year may be associated with an increased risk of bladder cancer. Takeda said in a statement it is working with FDA to update the label and with regulatory agencies in Europe to

Read the full 535 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE